Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.78 |
| ▸ | HPGD | P15428 | 6/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.78 |
| ▸ | CA12 | O43570 | 1/20 | 0.78 |
| ▸ | CA1 | P00915 | 1/20 | 0.78 |
| ▸ | CA2 | P00918 | 1/20 | 0.78 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.78 |
| ▸ | CA4 | P22748 | 1/20 | 0.78 |
| ▸ | CA6 | P23280 | 1/20 | 0.78 |
| ▸ | CA7 | P43166 | 1/20 | 0.78 |
| ▸ | CA9 | Q16790 | 1/20 | 0.78 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.78 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | G6PD | P11413 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL4907211 | 0.98 | ALDH1A1 (0.75) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL15623328 | 0.98 | ALDH1A1 (0.75) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL1829341 | 0.93 | ALDH1A1 (0.82) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL8621859 | 0.92 | ALDH1A1 (0.72) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL294304 | 0.92 | ALDH1A1 (0.72) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL25288775 | 0.91 | ALDH1A1 (0.78) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL31332109 | 0.91 | ALDH1A1 (0.78) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL28366261 | 0.90 | ALDH1A1 (0.69) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Dodecane SCHEMBL6692297 | 0.90 | ALDH1A1 (0.69) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Hexadecane SCHEMBL28225619 | 0.90 | ALDH1A1 (0.69) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115666506-A | Cosmetic composition | 花王株式会社 | 2023-01-31 | — | — | CN | disclosed |
| CN-114377138-A | Method for stabilizing atherosclerotic plaques using lipoxins, resolvins and analogs thereof | 福塞斯儿童牙科医院 | 2022-04-22 | — | — | CN | disclosed |
| CN-107438366-B | Method for stabilizing atherosclerotic plaques using lipoxins, resolvins and analogs thereof | 福塞斯儿童牙科医院 | 2022-03-15 | — | — | CN | disclosed |
| EP-3743954-A1 | ELECTRODE MATERIAL COMPRISING CARBON-COATED TITANIUM DIOXIDE PARTICLES | Westfälische Wilhelms-Universität Münster (DE) | 2020-12-02 | — | — | EP | disclosed |
| CN-106632759-B | Solid catalyst component for ethylene polymerization, preparation and application thereof | 中国石油化工股份有限公司 | 2020-09-15 | — | — | CN | disclosed |
| CN-110381976-A | COMPOSITIONS COMPRISING PEPTIDE WKDEAGKPLVK | 努里塔斯有限公司 | 2019-10-25 | — | — | CN | disclosed |
| CN-110101590-A | For handling the method and its kit of hair | 知识产权全资有限公司 | 2019-08-09 | — | — | CN | disclosed |
| CN-105267066-B | Method for treating hair and kit therefor | 知识产权全资有限公司 | 2019-06-11 | — | — | CN | disclosed |
| US-20180370905-A1 | Compounds Useful for the Treatment of Metabolic Disorders and Synthesis of the Same | NORTH CAROLINA CENTRAL UNIV (US) | 2018-12-27 | — | — | US | disclosed |
| US-10005720-B2 | Compounds useful for the treatment of metabolic disorders and synthesis of the same | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| EP-2691076-A1 | USNIC ACID TOPICAL FORMULATION | Evocutis plc (GB) | 2014-02-05 | — | — | EP | disclosed |
| EP-2691077-A1 | SALICYLIC ACID TOPICAL FORMULATION | Evocutis plc (GB) | 2014-02-05 | — | — | EP | disclosed |
| WO-2012172318-A1 | FORMULATIONS CONTAINING TROPOLONOIDS, COPPER SALT AND A SOLVENT SYSTEM | EVOCUTIS PLC (GB) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012131347-A1 | USNIC ACID TOPICAL FORMULATION | EVOCUTIS PLC (GB) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012131348-A1 | SALICYLIC ACID TOPICAL FORMULATION | EVOCUTIS PLC (GB) | 2012-10-04 | — | — | WO | disclosed |
| CN-102271655-A | Silicone paste compositions | — | 2011-12-07 | — | — | CN | disclosed |
| WO-2011001165-A2 | FORMULATIONS | SYNTOPIX GROUP PLC (GB) | 2011-01-06 | — | — | WO | disclosed |
| CN-101675912-A | cosmetic and dermatological formulations containing phenoxyalkyl esters | EVONIK GOLDSCHMIDT GMBH | 2010-03-24 | — | — | CN | disclosed |
| US-7316657-B2 | Massage appliance with adjustable massage characteristics and storage container | BEIERSDORF AG (DE) | 2008-01-08 | — | — | US | disclosed |
| US-20050059914-A1 | Massage appliance | BEIERSDORF AG | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005720-B2 | Compounds useful for the treatment of metabolic disorders and synthesis of the same | GLS2, PC, GLS | ALDH1A1 219/4885KDM4E 2153/4885HPGD 272/4885 |
| US-20180370905-A1 | Compounds Useful for the Treatment of Metabolic Disorders and Synthesis of the Same | GLS2, PC, GLS | ALDH1A1 219/4885KDM4E 2153/4885HPGD 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.